Text by Godfre Leung, Darsie Alexander, Maria Jose Herrera, Claudia Calirman, Erica Battle, Dvid Fehr, Luigia Lonardelli, Hiroko Ikegami, Ed Halter, Charlotte Cotton, Martin Harrison, Tom Pospiszyl
Primary antibodies used were: mouse monoclonal (IgG2A) anti-PSD-95 clone K28/43 (1:200, Neuromab, UC Davis, Davis, CA), mouse monoclonal IgG1 anti-PSD-95 clone 7E3-1B8 (1:250, Thermo Fisher Scientific, Waltham, MA, cat#: MA1-046) anti-guinea pig polyclonal anti-Bassoon (1:300, Synaptic Systems, Gottingen, Germany, cat# 141 004), rabbit polyclonal anti-Bassoon (1:300, Synaptic Systems, cat #: 141 003), chicken anti-GFP (1:2000, Abcam, Cambridge, MA, cat# ab13970), rabbit monoclonal anti-GluN1 (1:500, AB9864, Millipore Sigma), mouse monoclonal (IgG2A) anti-GluN2A clone N327/95 (1:250, Neuromab), mouse monoclonal (IgG2B) anti-GluN2B clone N59/36 (1:250, Neuromab), mouse monoclonal (IgG1) anti-GluA1 clone N355/11 (1:250, Neuromab), rabbit polyclonal anti-GluA2(1:500, Synaptic Systems, cat#: 182 103), mouse monoclonal (IgG2A) anti-Synaptotagmin 1 (1:500, Synaptic Systems, cat#: 105 011)
This organizational structure did not see any major changes over the next few years
4.4 Nanostructured lipid carriers NLCs are advanced lipid-based systems developed by incorporating both solid and liquid lipids (up to 30%), resulting in enhanced drug encapsulation, stability, and skin permeation
If youre interested in learning more about how targeted peptide therapy can help you achieve your fitness or recovery goals, reach out and schedule a complimentary consultation with Redefine Health and Wellness
